What is the recommended management for an infant with congenital diarrhea due to tufting enteropathy?

Management of Congenital Diarrhea Due to Tufting Enteropathy

Infants with tufting enteropathy require immediate initiation of total parenteral nutrition (TPN) as the primary treatment, with early referral to an intestinal rehabilitation center, and should be evaluated for intestinal transplantation candidacy given the high risk of death associated with this congenital mucosal disorder. 1

Immediate Nutritional Management

The cornerstone of tufting enteropathy management is aggressive nutritional support through TPN. All patients require high-calorie parenteral nutrition to achieve growth catch-up and prevent severe malnutrition 2. This is not a temporary measure—most patients remain TPN-dependent throughout childhood and often into adulthood 3, 4.

Key nutritional principles:

• Start TPN immediately upon diagnosis to prevent life-threatening dehydration, electrolyte imbalances, and malnutrition 5
• Provide high caloric intake via parenteral route as enteral tolerance is typically poor 2
• Monitor for TPN-related complications, particularly intestinal failure-associated liver disease (IFALD)

Enteral Nutrition Attempts

While TPN is essential, some enteral feeding should be attempted. In tufting enteropathy, general diet restriction is mainly supportive and rarely allows significant TPN weaning 6. Unlike other congenital diarrheas where nutrient elimination or supplementation can resolve symptoms, tufting enteropathy represents an epithelial polarity defect where dietary manipulation provides minimal benefit 6.

Important caveat: A small subset of patients may achieve partial enteral tolerance over time. One reported case showed a patient tolerating normal diet with only intermittent partial PN by age 3, though this is exceptional 3. Most patients require lifelong TPN support 4.

Early Referral to Specialized Centers

Immediate referral to an intestinal rehabilitation center with expertise in chronic intestinal failure is mandatory 1. These centers can:

• Optimize TPN formulations to prevent IFALD
• Manage central venous catheter complications
• Assess candidacy for intestinal transplantation
• Provide specialized multidisciplinary care

Intestinal Transplantation Evaluation

Tufting enteropathy is specifically listed as a "high risk of death attributable to underlying disease" indication for transplant assessment 1. Patients should be evaluated for intestinal transplantation candidacy early in their disease course, not waiting for TPN failure.

Specific transplant indications in tufting enteropathy:

1. Life-saving indications:

   • Impending or overt liver failure from IFALD (bilirubin >3-6 mg/dL, progressive thrombocytopenia, hepatosplenomegaly) 1
   • Central venous catheter thrombosis affecting ≥2 major central veins 1
   • Frequent central line sepsis (≥2 episodes/year requiring hospitalization, or single fungemia episode) 1

2. Congenital mucosal disorder status: Tufting enteropathy itself qualifies as a high-risk condition warranting transplant evaluation due to the inherent mortality risk 1

Critical distinction: Patients with IFALD-related liver failure or invasive desmoid tumors should be listed for life-saving transplantation 1. However, for other indications including the diagnosis of tufting enteropathy alone without complications, listing should be on a careful case-by-case basis 1.

Monitoring for Complications

TPN-related complications requiring surveillance:

• IFALD: Monitor hepatic aminotransferases, total bilirubin, albumin, INR, platelet count regularly 7
• Central line infections: Maintain strict catheter care protocols
• Venous thrombosis: Monitor patency of central access sites
• Growth parameters and developmental milestones

Unexpected complication: Chronic arthritis has been reported in tufting enteropathy patients, occurring in approximately 6 of 90 reported cases 3. Monitor for joint symptoms.

Prognosis and Realistic Expectations

The evidence shows sobering outcomes: Among 114 CTE patients with detailed treatment information, 108 required PN therapy with only 6 successfully weaned off 2. Of those followed, 30 patients (27.3%) died, including 5 post-transplant deaths 2.

Genotype considerations: Truncating EPCAM variants (nonsense, frameshift, large deletions) are significantly associated with TPN dependency compared to non-truncating variants (OR 2.37, p=0.020) 8. This information can help with prognostic counseling but does not change initial management.

Adjunctive Therapies

Monthly somatostatin therapy has been reported in one case to help manage symptoms 3, though evidence is extremely limited. This should not replace TPN but may be considered as adjunctive therapy in specialized centers.

Common Pitfalls to Avoid

• Delaying TPN initiation while attempting dietary modifications—tufting enteropathy does not respond to nutrient elimination or supplementation strategies 6
• Waiting for TPN failure before transplant evaluation—early assessment is recommended given the high mortality risk 1
• Underestimating caloric needs—aggressive high-calorie TPN is required for growth catch-up 2
• Missing IFALD development—regular liver function monitoring is essential as this becomes a life-saving transplant indication 1